CorMedix Inc. to Participate in Two Upcoming Investor Conferences
BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Antimicrobial
CorMedix Inc. Announces Notice of Allowance for U.S. Patent Application Covering Lead Product DefenCath
BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
Ceapro Inc. Appoints Michel Regnier as Senior Vice President, Technical Operations
Executive function to oversee Edmonton site technical operations with implementation of Pilot Unit for Pressurized Gas eXpanded (PGX) Technology as...
MI4, Montreal’s powerhouse of infectious disease research, celebrates five years of innovation and philanthropy
Vincent Chiara, real estate entrepreneur and founder and President of Groupe Mach donates $1.4 million to the MUCH Foundation for...
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, N.Y., April 26, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference
LEXINGTON, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
CorMedix Inc. Announces Regulatory, Manufacturing and Reimbursement Updates
BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and...
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Kane Biotech Announces Distribution Agreement with ProgenaCare Global for its coactiv+™ Antimicrobial Wound Gel
ProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care marketWINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) --...
Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients
- Interim blinded safety and pharmacokinetic data to be presented at the 33rd European Congress of Clinical Microbiology & Infectious...
AXIM® Biotechnologies Commences Commercial Manufacturing of FDA-Cleared Proprietary Ocular Diagnostic Assays
Leading Diagnostic Healthcare Company Begins Manufacturing of Ocular Immunoglobulin (IgE), Lactoferrin Tests to Fulfill Orders From Commercialization Partner SAN DIEGO,...
Paratek Pharmaceuticals Presenting New Data from NUZYRA® (omadacycline) and Investigator-Initiated Research Programs at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) 2023
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development...
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting
Oral Presentation of New Data Demonstrating the Activity of Lysin CF-370 Against XDR Pseudomonas aeruginosa New Data Elucidating the Mechanism...
Immuron Q3 Sales reach 150% of 1H Sales
Highlights: Australian Q3 FY23 sales of A$577 k (201% of 1H sales)North American Q3 FY23 Travelan® sales of A$298 k...
T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices
LEXINGTON, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens...
OpGen’s Subsidiary Curetis Signs Expansion of R&D Collaboration with FIND
Parties add several deliverables to initial R&D collaboration contractOverall potential revenue increased to up to euro 830 thousandROCKVILLE, Md., April...
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
YONKERS, New York, April 03, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the...
Aridis Provides Corporate Update
LOS GATOS, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS) (“Aridis” or the “Company”), a biopharmaceutical...
ContraFect Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Provides Business Update
YONKERS, N.Y., March 31, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery...
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize...